Ritter Pharmaceuticals Inc (RTTR.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2014||Executive Chairman of the Board, Chief Strategic Officer|
|57||2014||Chief Executive Officer, Director|
|52||2017||Principal Financial Officer, Principal Accounting Officer, Vice President - Finance|
|34||2014||President, Founder, Director|
- BRIEF-sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals
- BRIEF-RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE
- BRIEF-Ritter Pharmaceuticals Inc prices $23,000,000 public offering
- BRIEF-Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28
- BRIEF-Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms